Gemcitabine plus cisplatin

DRUG8 trials

Conditions

Adjuvant ChemotherapyBiliary Tract CancerBladder CancerBladder Urothelial CarcinomaCancerCapecitabineCholangiocarcinomaCisplatin

Phase 1

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

CompletedNCT00496275

Genzyme, a Sanofi CompanyNon Small Cell Lung Cancer

Start: 2006-08-31End: 2007-05-31Updated: 2016-08-26

Phase 2

Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma

CompletedNCT01375972

Asan Medical CenterMetastatic Biliary Cancer

Start: 2008-03-31End: 2011-08-31Updated: 2011-12-06

Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression

NCT01401192

Samsung Medical CenterNon-small Cell Lung Cancer

Start: 2011-07-31Target: 304Updated: 2011-07-25

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

CompletedNCT03079427

Asan Medical CenterAdjuvant Chemotherapy, Biliary Tract Cancer, Capecitabine +3

Start: 2017-05-15End: 2022-11-15Updated: 2022-12-06

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

CompletedNCT04570410

The First Affiliated Hospital with Nanjing Medical UniversityBladder Urothelial Carcinoma

Start: 2020-12-01End: 2024-04-15Updated: 2025-08-05

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

RecruitingNCT07569679

Air Force Military Medical University, ChinaBiliary Tract Cancer

Start: 2025-12-10End: 2028-12-30Target: 124Updated: 2026-05-06

Phase 3

Comparative Study between Gemcitabine Plus Cisplatin and Docetaxel Plus Fluorouracil Plus Cisplatin as Induction Chemotherapy in Unresectable Locally Advanced Head and Neck Cancer Patients

RecruitingPACTR202406479424515

Suez Canal UniversityCancer

Start: 2023-01-01Target: 20Updated: 2026-09-14

Unknown Phase

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

CompletedNCT01801644

Barmherzige Brüder ViennaBladder Cancer

Start: 2007-04-30End: 2013-02-28Updated: 2013-03-01

2025-12-01

Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma.

2025-08-11

Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma

Journal of Hepatology2024-11-1015 citations

Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.

Journal of Clinical Oncology2024-01-293 citations

Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.

Journal of Clinical Oncology2023-06-0111 citations

Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer.

Journal of Clinical Oncology2023-06-01

Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).

Journal of Clinical Oncology2022-06-0117 citations

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.

2022-05-0656 citations

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

BMC Cancer2021-07-1610 citations